SCHEMBL24624869

SCHEMBL24624869

CS/C(=N\C(C)C)NC(C)=O

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 1/20 0.32
EPHX1 P07099 1/20 0.32
TAS2R38 P59533 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19251591 1.00 CRBN (0.32) CRBNEPHX1TAS2R38
SCHEMBL3753647 0.75
SCHEMBL3753641 0.75
SCHEMBL11675748 0.74 ABCC1 (0.33)
SCHEMBL6560044 0.73 CRBN (0.35) CRBNTAS2R38
SCHEMBL6560042 0.73 CRBN (0.35) CRBNTAS2R38
SCHEMBL10170621 0.73 CRBN (0.35) CRBNTAS2R38
SCHEMBL21363809 0.73 ANPEP (0.32)
SCHEMBL11698336 0.71 CRBN (0.33) CRBNEPHX1TAS2R38
Iodide SCHEMBL11701772 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11542262-B2 Phosphatidylinositol 3-kinase inhibitors NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2023-01-03 US disclosed
US-20220220113-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2022-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542262-B2 Phosphatidylinositol 3-kinase inhibitors PI4KB, PI4KA, PIK3CD CRBN 2240/4885EPHX1 3881/4885TAS2R38 4626/4885
US-20220220113-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS PI4KB, PI4KA, PIK3CD CRBN 2240/4885EPHX1 3881/4885TAS2R38 4626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.